Be the first to like this
After the failure of a non-steroidal aromatase inhibitor (nsAI) for postmenopausal patients with metastatic breast cancer (mBC), it is unclear which of various kinds of endocrine therapy is the most appropriate. A randomized controlled trial was performed to compare the
efficacy and safety of daily toremifene 120 mg (TOR120), a selective estrogen receptor
modulator, and exemestane 25 mg (EXE), a steroidal aromatase inhibitor. The primary end point was the clinical benefit rate (CBR). The secondary end points were objective response
rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicity.